Reactive plasmacytoses in multiple myeloma during hematopoietic recovery with G- or GM-CSF.
We report on three cases of reactive plasmacytoses (RP) in the course of multiple myeloma (MM). The three patients achieved complete remission following high dose melphalan and peripheral blood stem cell transplantation. These transient plasmacytoses had all the characteristics of RP, i.e. expansion of highly proliferative polyclonal plasma cells (PC) with a normal phenotype and genotype and corresponding to expansion of both PC progenitors (plasmablasts) and PC precursors (early plasma cells). These cells were easily distinguished from malignant PC of the corresponding patients evaluated at diagnosis, especially by their phenotypic and genotypic features.
Jego
G
G
Oncogénèse Immunohématologique, INSERM U463, Nantes, France.
Avet-Loiseau
H
H
Robillard
N
N
Moreau
P
P
Amiot
M
M
Harousseau
J
J
Pellat-Deceunynck
C
C
Bataille
R
R
D005260:Female; D005434:Flow Cytometry; D005838:Genotype; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008218:Lymphocytosis / Q000150:complications*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D010641:Phenotype; D010950:Plasma Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology*
D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D008558:Melphalan